Skip to content

Construction and evaluation of executive function intervention program for patients with vascular mild cognitive impairment by immersive exercise and cognitive training

Construction and evaluation of executive function intervention program for patients with subcortical ischemic vascular cognitive impairment by immersive exercise and cognitive training

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048696
Enrollment
Unknown
Registered
2021-07-12
Start date
2021-05-01
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular cognitive impairment

Interventions

Experimental group:Immersive exercise and cognitive training in hospital
/control group:Traditional sports and cognitive training at home

Sponsors

Xuanwu Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male and female aged >= 50 years old; 2. Clinical diagnosis: vascular mild cognitive impairment; 3. Imaging data: Lacunar infarction, white matter degeneration, vasculitis and other small vessel disease-related pathological injury. 4. Cognitive function: (1) The chief complaint or informed person reported that the patient had cognitive impairment in related memory or other cognitive domains for at least 3 months; (2) Mini Mental State Assessment Scale (MMSE) >=20 (primary school) or >=24 (secondary school or above); (3) The score of tat a or B was higher than or equal to the normal threshold.

Exclusion criteria

Exclusion criteria: (1) Imaging: no cortical and / or subcortical non lacunar infarction, cerebral hemorrhage, white matter special causes (multiple sclerosis, sarcoidosis, brain radiotherapy); (2) Brain diseases: Alzheimer's disease, Lewy body dementia, frontotemporal dementia, Parkinson's disease, tumor, hydrocephalus, trauma, syphilis, acquired immune deficiency syndrome, Creutzfeldt Jakob disease, etc; (3) Other types of neurological diseases: Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, etc; (4) Malignant and critical diseases: malignant diseases (such as advanced tumors), severe cardiovascular diseases (such as severe aortic stenosis, obstructive hypertrophic heart disease, etc.), severe chronic renal insufficiency, severe chronic obstructive pulmonary disease, epilepsy, etc; (5) Dyskinesia: musculoskeletal diseases (such as severe lower extremity osteoarthritis) and history of knee / hip arthroplasty; (6) Other diseases: vertigo syndrome, extrapyramidal symptoms or other diseases limit the patients participating in the intervention; (7) Drugs: those who are taking drugs to treat mild cognitive impairment; Taking benzodiazepines, antipsychotics or antiepileptics and other drugs that may affect cognitive function and drug abuse, alcohol and drug abuse, poisoning and metabolic abnormalities; (8) Emotion: serious anxiety, depression or other mental illness; (9) Audiovisual impairment: severe loss of vision, hearing impairment, severe aphasia or other factors that may hinder the completion of neuropsychological assessment or brain MRI examination; (10) I'm taking part in another experiment.

Design outcomes

Primary

MeasureTime frame
Executive function;

Secondary

MeasureTime frame
general cognitive functio;Balance function;

Countries

China

Contacts

Public ContactChang Hong

School of nursing, Capital Medical University

changhong19791111@126.com+86 13701034090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026